Travere Therapeutics Inc (TVTX : NASDAQ)
Common Stock
$50.84
USD
-0.04 (-0.07%)
Last updated: 2026-10-28
Follow TVTX
TVTX
Travere Therapeutics Inc
WealthAwesomePerformance
1 Day
-0.07%
1 Week
-3.30%
1 Month
-17.42%
YTD
-6.09%
Key Statistics
Market Cap
$4.73B
52W High
$68.73
52W Low
$22.59
P/E Ratio
-
50 Day MA
$59.91
200 Day MA
$46.32
Beta
1.14
Dividend Yield
-
Technical Indicators
Price vs 50-Day SMA
Price vs 200-Day SMA
Recent Price History
| Date | Open | High | Low | Close | Adj Close | Volume |
|---|---|---|---|---|---|---|
| 10/28/2026 | $50.20 | $50.91 | $49.52 | $50.84 | $50.84 | 1,508,566 |
| 10/27/2026 | $49.85 | $51.00 | $49.29 | $50.88 | $50.88 | 3,307,818 |
| 10/26/2026 | $50.52 | $51.32 | $49.24 | $49.97 | $49.97 | 3,327,744 |
| 10/23/2026 | $52.00 | $52.22 | $49.78 | $50.08 | $50.08 | 2,314,500 |
| 10/22/2026 | $52.34 | $53.12 | $51.25 | $52.43 | $52.43 | 1,774,177 |
| 10/21/2026 | $52.88 | $54.83 | $52.50 | $52.58 | $52.58 | 2,164,172 |
| 10/20/2026 | $50.43 | $52.70 | $50.40 | $52.30 | $52.30 | 1,886,724 |
| 10/19/2026 | $50.17 | $51.28 | $49.74 | $50.49 | $50.49 | 1,296,193 |
| 10/16/2026 | $52.56 | $52.56 | $49.46 | $49.60 | $49.60 | 1,827,900 |
| 10/15/2026 | $53.94 | $55.57 | $52.63 | $52.79 | $52.79 | 1,980,616 |
Analyst Price Targets
Based on 15 analysts covering TVTX · as of Oct 5, 2026
Wall Street analysts forecast TVTX stock price to rise 47.9% over the next 12 months.
Consensus
Strong Buy4.73 / 5.00
Avg. Target
US$75.21
+47.9% Upside
Current Price
US$50.84
Last close
Analyst Breakdown (15 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on TVTX's historical volatility
30-Day Vol
39.9%
Annualized
90-Day Vol
38.8%
Annualized
Trend (90d)
-40.7%
Annualized drift
90d Mean
US$43.96
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | US$48.44 | US$42.21 – US$55.58 |
| 60 trading days | US$46.15 | US$37.99 – US$56.06 |
| 90 trading days | US$43.96 | US$34.64 – US$55.79 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Financials
- Revenue (TTM)
- $591.33M
- EBITDA
- $22.91M
- Profit Margin
- -7.35%
- ROE (TTM)
- -236.36%
- EPS (Diluted)
- -0.74
- Book Value
- 0.26
Classification
- Sector
- Health Care
- Industry
- Biotechnology
- Group
- Pharmaceuticals, Biotechnology & Life Sciences
7 stocks to buy and hold forever
Blue-chip dividend stocks for long-term wealth building.
Get the FREE ReportExplore More
Common Questions About TVTX.US
Market movers
Recent NASDAQ movers
Top 1-day gainers — updated from our Canadian movers feed.
| Ticker | Name | Price | 1D |
|---|---|---|---|
| AXG | Solowin Holdings | $5.68 | +14100.00% |
| ATYR | aTyr Pharma, Inc. | $5.14 | +4041.94% |
| OMEX | Odyssey Marine Exploration Inc | $13.55 | +2418.59% |
| HVII | Hennessy Capital Investment Corp. VII Ordinary Shares | $4.46 | +243.08% |
| ULBI | Ultralife Corporation | $15.61 | +145.44% |
| ATII | Archimedes Tech SPAC Partners II Co. Ordinary Shares | $9.81 | +110.06% |
| RITRF | Reitar Logtech Holdings Limited | $0.02 | +86.09% |
| KPTI | Karyopharm Therapeutics Inc | $0.83 | +73.35% |
TVTX.US news timeline
1 article covering TVTX.US, most recent first
Latest